Precision Biologics’ Collaborators at NHLBI/NIH and U Va to Reveal New AML Target for CAR-NK at American Association for Cancer Research (AACR) Annual Meeting on April 19th, 2026, San Diego, CA

Truncated Core 1 O-glycans recognized by Precision Biologics’ monoclonal antibody (mAb) NEO-201 are discovered as a novel Acute Myeloid Leukemia (AML) associated antigen present across multiple subtypes and largely absent from early hematopoietic progenitors. Tests show potent antileukemic activity of NEO-201CAR NK cells in preclinical data.